Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fagan

Showing results (481-490 of 489) with videos related to

Pageof 49
Sort By:
You have reached the last page of results.This site can display upto 489 results.
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|October 28, 2017
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological PsychiatryPiotr Lewczuk, Peter Riederer, Sid E O'Bryant, et al.
Molecular Psychiatry|March 23, 2019
The BDNF<sub>Val66Met</sub> SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's diseaseNicolai Franzmeier, Jinyi Ren, Alexander Damm, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 26, 2011
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkersNiklas Mattsson, Ulf Andreasson, Staffan Persson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 31, 2018
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's diseaseNiklas Mattsson, Colin Groot, Willemijn J Jansen, et al.
JAMA Psychiatry|December 1, 2017
Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without DementiaWillemijn J Jansen, Rik Ossenkoppele, Betty M Tijms, et al.
JAMA|May 20, 2015
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysisWillemijn J Jansen, Rik Ossenkoppele, Dirk L Knol, et al.
JAMA Neurology|January 31, 2022
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical SpectrumWillemijn J Jansen, Olin Janssen, Betty M Tijms, et al.
Pageof 49

Showing results (481-490 of 489) with videos related to

Sort By:
Pageof 49
You have reached the last page of results.This site can display upto 489 results.
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|October 28, 2017
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological PsychiatryPiotr Lewczuk, Peter Riederer, Sid E O'Bryant, et al.
Molecular Psychiatry|March 23, 2019
The BDNF<sub>Val66Met</sub> SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's diseaseNicolai Franzmeier, Jinyi Ren, Alexander Damm, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 26, 2011
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkersNiklas Mattsson, Ulf Andreasson, Staffan Persson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 31, 2018
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's diseaseNiklas Mattsson, Colin Groot, Willemijn J Jansen, et al.
JAMA Psychiatry|December 1, 2017
Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without DementiaWillemijn J Jansen, Rik Ossenkoppele, Betty M Tijms, et al.
JAMA|May 20, 2015
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysisWillemijn J Jansen, Rik Ossenkoppele, Dirk L Knol, et al.
JAMA Neurology|January 31, 2022
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical SpectrumWillemijn J Jansen, Olin Janssen, Betty M Tijms, et al.
Pageof 49